Skip to content
Optellum
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales
Menu Close
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

News & Events

News in brief: innovations to tackle patient backlog and cancer care, first clinical use of accessible incubator

  • Post author:Rhiannon Lassiter
  • Post published:November 29, 2021
  • Post category:Media

Health Tech Newspaper

Read more articles

Previous PostGE Healthcare doubles down on AI with new product launches, partnerships with Optellum and Cambridge
Next PostOptellum and GE Healthcare to advance AI-powered lung cancer diagnosis

You Might Also Like

Read more about the article Optellum/J&J mentioned in the daily news roundup (subscription required)

Optellum/J&J mentioned in the daily news roundup (subscription required)

August 18, 2021
Read more about the article Optellum teams up with Johnson & Johnson

Optellum teams up with Johnson & Johnson

August 19, 2021
Read more about the article The end of a death sentence: Václav Potěšil wants to detect cancer using artificial intelligence

The end of a death sentence: Václav Potěšil wants to detect cancer using artificial intelligence

August 9, 2021
  • Back to News & Events

Recent Posts

  • AtlantiCare First in Northeast to Deploy Optellum AI Alongside Robotics for Early Lung Cancer Diagnosis and Treatment
  • Jason Pesterfield, Optellum CEO, appears on Houston Innovators podcast
  • 150 most promising digital health companies of 2022, according to CB Insights
  • Lung Cancer Awareness Month: Optellum’s AI platform demonstrates a vital role in efficient diagnosis to improve lung cancer survival rates
  • Pulmonary advances and clinical collaborations at CHEST 2022

Our Mission

Optellum was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, and cured.  Our vision is to redefine early intervention of diseases like lung cancer, by enabling every clinician, in every hospital, to make the right decisions and give their patients the best chance to fight back.

Optellum Ltd.

  • Oxford Centre for Innovation
    Oxford, OX1 1BY
    United Kingdom
  • info@optellum.comOpens in your application

Optellum Inc.

  • TMC Innovation Institute
    2450 Holcombe Blvd, Suite X
    Houston, TX 77021
    United States

Pages

  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

Follow Us

  • Opens in a new tab
  • Opens in a new tab

Certifications

Copyright 2023 - Optellum Ltd | Privacy Policy
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}